First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
This collaboration aims to combine Molcure’s cutting-edge AI technology with Boehringer Ingelheim’s extensive expertise in drug discovery
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
Pioneering innovation aims to transform anticoagulant therapy and improve patient outcomes
Subscribe To Our Newsletter & Stay Updated
